Human CD30 Ligand/TNFSF8 Antibody (116614)

R&D Systems | Catalog # MAB1028

R&D Systems
Loading...

Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Neutralization, Flow Cytometry, CyTOF-ready

Cited:

Flow Cytometry

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2B Clone # 116614
Loading...

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human CD30 Ligand/TNFSF8
Gln63-Asp234
Accession # P32971

Specificity

Detects human CD30 Ligand/TNFSF8 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) CD27 Ligand, recombinant mouse CD30 Ligand, or rhCD40 Ligand is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2B

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human CD30 Ligand/TNFSF8 Antibody (116614)

Detection of CD30 Ligand/TNFSF8 antibody in Human PBMCs antibody by Flow Cytometry.

Detection of CD30 Ligand/TNFSF8 in Human PBMCs by Flow Cytometry.

Human peripheral blood mononuclear cells (PBMCs) treated with 50 ng/mL PMA and 200 ng/mL Calcium Ionomycin overnight were stained with Mouse Anti-Human CD3e APC-conjugated Monoclonal Antibody (Catalog # FAB100A) and either (A) Mouse Anti-Human CD30 Ligand/TNFSF8 Monoclonal Antibody (Catalog # MAB1028) or (B) Mouse IgG2BIsotype Control (Catalog # MAB004) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). View our protocol for Staining Membrane-associated Proteins.
IL‑6 Secretion Induced by CD30 Ligand/TNFSF8 and Neutralization by Human CD30 Ligand/TNFSF8 Antibody.

IL‑6 Secretion Induced by CD30 Ligand/TNFSF8 and Neutralization by Human CD30 Ligand/TNFSF8 Antibody.

In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (10 µg/mL, Catalog # MAB050), Recombinant Human CD30 Ligand/TNFSF8 (Catalog # 1028-CL) stimulates IL-6 secretion in the HDLM human Hodgkin’s lymphoma cell line in a dose-dependent manner (orange line), as measured by the Human IL-6 Quantikine ELISA Kit (Catalog # D6050). Under these conditions, IL-6 secretion elicited by Recombinant Human CD30 Ligand/TNFSF8 (1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CD30 Ligand/TNFSF8 Monoclonal Antibody (Catalog # MAB1028). The ND50 is typically 1-4 µg/mL.
Detection of CD30 Ligand/TNFSF8 by Western Blot

Detection of CD30 Ligand/TNFSF8 by Western Blot

Iso2 partially blocks Iso1-mediated stimulation of K299 cells. (A) HEK cells were transfected with either vector (vec) control or untagged Iso1 (1NT) with or without untagged Iso2 (2NT) or FLAG-tagged Iso2 (2FL). Transfected HEK cells were co-cultured with a K299-NFkB-Luc reporter clonal line. Two asterisks indicate p ≤ 0.01, three indicate p ≤ 0.001, and four indicate p ≤ 0.0001. (B,C) HEK cells were transfected with increasing quantities of 1NT plasmid with either vec or 2NT at a constant quantity, and then co-cultured with the K299-NFkB-Luc reporter line. Reporter activity (B) and IL-6 production (C) were measured. (D) HEK cells were transfected with either 1NT and vec or Iso2 and assessed for 1NT expression by flow cytometry. (E) Cells were transfected with increasing quantities of 1NT and either vec or 2FL, and the lysates were subject to SDS-PAGE and Western blot using a pan-CD30L antibody. Densitometry was used to quantify Iso1 bands, normalizing to GAPDH. Error bars for all are from standard deviations between technical replicates; representative experiment of ≥3 shown. Image collected and cropped by CiteAb from the following open publication (https://www.mdpi.com/1467-3045/46/3/172), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD30 Ligand/TNFSF8 by Flow Cytometry

Detection of CD30 Ligand/TNFSF8 by Flow Cytometry

Iso2 partially blocks Iso1-mediated stimulation of K299 cells. (A) HEK cells were transfected with either vector (vec) control or untagged Iso1 (1NT) with or without untagged Iso2 (2NT) or FLAG-tagged Iso2 (2FL). Transfected HEK cells were co-cultured with a K299-NFkB-Luc reporter clonal line. Two asterisks indicate p ≤ 0.01, three indicate p ≤ 0.001, and four indicate p ≤ 0.0001. (B,C) HEK cells were transfected with increasing quantities of 1NT plasmid with either vec or 2NT at a constant quantity, and then co-cultured with the K299-NFkB-Luc reporter line. Reporter activity (B) and IL-6 production (C) were measured. (D) HEK cells were transfected with either 1NT and vec or Iso2 and assessed for 1NT expression by flow cytometry. (E) Cells were transfected with increasing quantities of 1NT and either vec or 2FL, and the lysates were subject to SDS-PAGE and Western blot using a pan-CD30L antibody. Densitometry was used to quantify Iso1 bands, normalizing to GAPDH. Error bars for all are from standard deviations between technical replicates; representative experiment of ≥3 shown. Image collected and cropped by CiteAb from the following open publication (https://www.mdpi.com/1467-3045/46/3/172), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD30 Ligand/TNFSF8 by Western Blot

Detection of CD30 Ligand/TNFSF8 by Western Blot

Iso2 can block Iso1/CD30 interaction and anti-Iso1 antibody binding. (A) HEK cells were transfected with increasing quantities of untagged Iso1 (1NT) plasmid with a constant amount of either vector (vec) control or FLAG-tagged Iso2 (2FL). Lysates were used in a plate-based binding assay using CD30 recombinant protein as the capture and an Iso1-specific anti-CD30L antibody was used for detection. (B) HEK cells were transfected with 1NT with or without 2FL, and 2FL alone. The lysates were used in a plate-based binding assay using an anti-pan-CD30L antibody for capture and an Iso1-specific anti-CD30L antibody for detection. (C,D) HEK cells were transfected with two quantities of 1NT and a constant quantity of 2FL or vector (vec) control in 10 cm plates. Additionally, 10% of the lysates were set aside as the input whole-cell lysate fraction (C), and the remainder was incubated with CD30-Fc recombinant protein and protein A/G beads (D). Both were subject to SDS-PAGE and Western blot. Error bars for all are from standard deviations between technical replicates; representative experiment of ≥3 shown. Image collected and cropped by CiteAb from the following open publication (https://www.mdpi.com/1467-3045/46/3/172), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human CD30 Ligand/TNFSF8 Antibody (116614)

Application
Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

0.25 µg/106 cells
Sample: Human peripheral blood mononuclear cells (PBMCs) treated with PMA and Calcium Ionomycin

Neutralization

Measured by its ability to neutralize CD30 Ligand/TNFSF8-induced IL‑6 secretion in the HDLM human Hodgkin’s lymphoma cell line. The Neutralization Dose (ND50) is typically 1-4 µg/mL in the presence of 1 µg/mL Recombinant Human CD30 Ligand/TNFSF8 and 10 µg/mL of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody.

Reviewed Applications

Read 1 review rated 3 using MAB1028 in the following applications:

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

  • Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
  • Spillover Popups - Visualize the spectra of individual fluorochromes
  • Antigen Density Selector - Match fluorochrome brightness with antigen density
Build Your Panel Now

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.


Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: CD30 Ligand/TNFSF8

CD30 ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells. The specific receptor for CD30L is CD30/TNFRSF8, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using the monoclonal antibody Ki-1. CD30 is also expressed on different non-Hodgkin's lymphomas, virus-infected T and B cells, and on normal T and B cells after activation. Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4+/CD8+ thymocytes that coexpress CD45RO and IL-4 receptor. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis. CD30 can act as a costimulatory molecule in thymic negative selection and may also play a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. Human and mouse CD30 ligand cDNAs share 70% sequence homology.

References

  1. Brunangelo, F. et al. (1995) Blood 85:1.
  2. Gruss, H.-J. and F. Herrmann (1996) Leukemia and Lymphoma 20:397.
  3. Chiarle, R. et al. (1999) J. Immunol. 163:194.

Alternate Names

CD153, CD30L, TNFSF8

Entrez Gene IDs

944 (Human); 21949 (Mouse)

Gene Symbol

TNFSF8

UniProt

Additional CD30 Ligand/TNFSF8 Products

Product Documents for Human CD30 Ligand/TNFSF8 Antibody (116614)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human CD30 Ligand/TNFSF8 Antibody (116614)

For research use only

Citations for Human CD30 Ligand/TNFSF8 Antibody (116614)

Customer Reviews for Human CD30 Ligand/TNFSF8 Antibody (116614) (1)

3 out of 5
1 Customer Rating
5 Stars
0%
4 Stars
0%
3 Stars
100%
2 Stars
0%
1 Stars
0%

Have you used Human CD30 Ligand/TNFSF8 Antibody (116614)?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 for a review with an image

$10/€7/£6/$10CAN/¥1110 for a review without an image

Submit a review
Amazon Gift Card
Showing  1 - 1 of 1 review Showing All
Filter By:
  • Name: Anonymous
    Application: ELISA
    Sample Tested: 293T human embryonic kidney cell line
    Species: Human
    Verified Customer | Posted 06/04/2019

There are no reviews that match your criteria.

Showing  1 - 1 of 1 review Showing All

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies